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INTRODUCTION
Percutaneous transthoracic needle lung biopsies (PTNBs) 
are useful procedures for patients with pulmonary lesions 
considered to be malignant. The accuracy of PTNBs for 
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Objective: To measure the diagnostic accuracy of percutaneous transthoracic needle lung biopsies (PTNBs) on the basis of 
the intention-to-diagnose principle and identify risk factors for diagnostic failure of PTNBs in a multi-institutional setting.
Materials and Methods: A total of 9384 initial PTNBs performed in 9239 patients (mean patient age, 65 years [range, 20–99 
years]) from January 2010 to December 2014 were included. The accuracy, sensitivity, specificity, positive predictive value 
(PPV), and negative predictive value (NPV) of PTNBs for diagnosis of malignancy were measured. The proportion of diagnostic 
failures was measured, and their risk factors were identified.
Results: The overall accuracy, sensitivity, specificity, PPV, and NPV were 91.1% (95% confidence interval [CI], 90.6–
91.7%), 92.5% (95% CI, 91.9–93.1%), 86.5% (95% CI, 85.0–87.9%), 99.2% (95% CI, 99.0–99.4%), and 84.3% (95% CI, 
82.7–85.8%), respectively. The proportion of diagnostic failures was 8.9% (831 of 9384; 95% CI, 8.3–9.4%). The independent 
risk factors for diagnostic failures were lesions ≤ 1 cm in size (adjusted odds ratio [AOR], 1.86; 95% CI, 1.23–2.81), lesion 
size 1.1–2 cm (1.75; 1.45–2.11), subsolid lesions (1.81; 1.32–2.49), use of fine needle aspiration only (2.43; 1.80–3.28), 
final diagnosis of benign lesions (2.18; 1.84–2.58), and final diagnosis of lymphomas (10.66; 6.21–18.30). Use of cone-
beam CT (AOR, 0.31; 95% CI, 0.13–0.75) and conventional CT-guidance (0.55; 0.32–0.94) reduced diagnostic failures.
Conclusion: The accuracy of PTNB for diagnosis of malignancy was fairly high in our large-scale multi-institutional cohort. 
The identified risk factors for diagnostic failure may help reduce diagnostic failure and interpret the biopsy results.
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diagnosis of malignancy has been reported to be high as 
90–99% (1-8). However, diagnostic failures often occur, 
and they hinder proper and timely management of patients. 
Diagnostic failures of PTNBs can be divided into false-
positive and false-negative results and non-evaluable 
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results due to insufficient specimens (3, 4). 
When biopsy results are non-evaluable due to insufficient 
specimens, the uncertainty over diagnoses remains 
unsolved, and additional medical procedures are required to 
confirm diagnoses. Therefore, non-evaluable results due to 
insufficient specimens should be considered as diagnostic 
failures irrespective of whether the final diagnosis is 
benign or malignant. According to the intention-to-
diagnose principle, non-evaluable results due to insufficient 
specimens should be counted as false-negative findings 
when calculating sensitivity and false-positive findings 
when calculating specificity (9). Thus, an understanding 
of the actual, realistic diagnostic accuracy of PTNBs is 
essential for deciding whether to perform a biopsy or 
not. However, there is a possibility that the sensitivity 
and specificity of PTNBs are overestimated because the 
majority of the studies did not follow the intention-to-
diagnose principle (9). Indeed, previous studies excluded 
non-evaluable results (1, 4, 8), regarded non-evaluable 
results as negative results (7), or did not mention how they 
handled non-evaluable results (5, 6) when they calculated 
the diagnostic accuracies.
To date, multiple studies have measured the diagnostic 
accuracy of PTNBs and investigated the risk factors 
for diagnostic failures (1-8, 10). Nonetheless, the 
generalizability of these studies is limited, because the 
majority were single-center studies (1-4, 6, 8, 10), had 
small numbers of patients (1, 2, 4, 8, 10), and limited 
patient inclusion to specific groups using particular guiding 
modalities (1-8, 10), biopsy needles (1-3, 6, 7, 10), and 
lesion sizes (2, 4). Moreover, the results of previous studies 
were inconsistent in relation to the effects of lesion 
size (3, 6, 8), lesion location (3, 4, 6), lesion depth (2, 
6), lesion type (6, 10), biopsy needle (1, 4), number of 
tissue samplings (3, 6), and final diagnosis (3, 4, 8) on 
diagnostic failures. Therefore, this study aimed to measure 
the diagnostic accuracy based on the intention-to-diagnose 
principle and identify risk factors for diagnostic failure of 
PTNBs in a multi-institutional setting. 
MATERIALS AND METHODS
Study Design and Study Population
This retrospective multi-institutional study was conducted 
by the Korean Registry of Percutaneous Transthoracic Needle 
Lung Biopsy group. Eight teaching hospitals in metropolitan 
Seoul (six tertiary and two secondary hospitals, with a 
median bed number of 979, ranging from 555 to 2320) 
participated in this study. The study was approved by the 
Institutional Review Board of each institution, and the 
requirement for informed consent was waived.
We enrolled all consecutive patients at least 20 years 
of age who had undergone PTNBs from January 2010 to 
December 2014. During this period, 10568 consecutive 
PTNBs were performed in 9823 patients. Among the 10568 
PTNBs, 1184 biopsies were excluded because they did not 
fulfill the predefined criteria for determining the final 
diagnosis (n = 590) or were repeat biopsies or re-biopsies 
of the same target lesion (n = 594). Finally, the remaining 
9384 PTNBs on 9239 patients were included. In two recent 
studies, we used the same patient cohort to report the 
malignancy risk of non-diagnostic results from PTNBs and 
complications of PTNBs by using CT-guidance modalities 
(11, 12). Unlike these previous studies, the current study 
primarily focuses on measuring diagnostic accuracy and 
identifying risk factors for diagnostic failures of PTNBs.
Procedures 
The biopsy procedures were performed in accordance 
with the routine clinical practice at each institution. The 
attending physicians requested the biopsy, and the final 
decision to perform PTNB was made at the discretion of 
dedicated thoracic radiologists in each institution. The 
selection of guiding modality and biopsy needle was 
made based on each institution’s resources, preference 
of the performing thoracic radiologists, and target lesion 
characteristics. Most procedures were performed by 
attending radiologists. In cases wherein the procedures 
were performed by radiology residents or fellows, attending 
radiologists closely supervised the procedure. On-site 
cytopathology technologists were not available at any 
hospital.
Data Collection
Site investigators and trained research assistants recorded 
the variables related to patients, target lesions, and biopsy 
procedures. The patient variables were age, sex, familial 
history of lung cancer, smoking history (never smoker, 
former smoker, or current smoker) (13), and the presence 
of pulmonary emphysema on CT images. The target lesion 
variables included size (long-axis diameter on axial CT 
images), type (solid or subsolid), location (upper and 
middle lobes or lower lobe), and depth (distance from the 
pleura to the target). The procedure variables included 
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biopsy needle (fine needle aspiration [FNA] or core needle 
biopsy [CNB], or combined), guiding modality (fluoroscopy, 
conventional CT, CT fluoroscopy, cone-beam CT [CBCT], or 
ultrasonography), and the number of tissue samplings. 
The original pathological reports of the PTNBs were 
also recorded. PTNB results were categorized as positive, 
negative, or non-evaluable due to insufficient specimens 
based on the original pathological reports, while the 
reference standard results were blinded. Malignancy, atypical 
cells suggestive of malignancy, atypical cells suspicious 
for malignancy, and atypical cells of indeterminate 
malignancy were considered positive, on the basis of our 
previous work (11). Specific benign, nonspecific benign 
pathological results, and atypical cells favoring benignity 
were considered negative. Non-evaluable results due to 
insufficient specimens was considered when the original 
pathologic reports indicated that the specimen was 
inadequate or insufficient for pathologic diagnosis. 
Reference Standards
For each lesion, the final diagnosis was categorized as 
malignant or benign by site investigators using predefined 
criteria. The reference standard for each target lesion was 
identified as follows (3, 6). First, the diagnosis was based 
on a surgical pathologic report if the lesion was surgically 
resected. Second, it was based on pathologic analysis of a 
non-surgical biopsy of the lesion if it revealed a malignant 
or specific benign result. Because atypical cell results were 
not considered as specific diagnoses, a final diagnosis was 
not determined based on the atypical cell results. Third, the 
lesion was identified as benign when its diameter decreased 
by 20% or more or its size was stable for at least two 
years without treatment. Fourth, the lesion was identified 
as malignant when the clinical behavior showed obvious 
malignant processes. Lesions that did not fit the criteria 
were classified as having incomplete reference standards, 
and they were excluded from this study.
Statistical Analyses
The sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV) for the diagnosis of 
malignancy were calculated with 95% confidence intervals 
(CIs) on a per-lesion basis. According to the intention-to-
diagnose principle, non-evaluable results due to insufficient 
specimens were considered as false negatives when 
calculating sensitivity and false positives when calculating 
specificity (9).
All biopsies were categorized as diagnostic successes 
or diagnostic failures. Diagnostic successes consisted of 
the true-positive and true-negative results. Diagnostic 
failures consisted of the false-positive, false-negative, 
and non-evaluable results due to insufficient specimens. 
To determine the risk factors for diagnostic failures, 
univariable and multivariable analyses were performed by 
using a generalized linear mixed model. The institutions 
were entered into the model as a random effect to account 
for the clustering effect. In the univariable analyses, 
variables related to the patients, target lesions, and biopsy 
procedures, a final diagnosis of benignity/malignancy, and 
final diagnosis of lymphomas were tested based on clinical 
contexts. Significant variables with p values less than 0.05 
in the univariable analyses were used as input variables 
for the multivariable analysis to identify independent 
risk factors. Because missing data consisted of only 3.3% 
(308 of 9384) of biopsy cases, multivariable analysis was 
performed based on a complete-case analysis. P values 
less than 0.05 were considered statistically significant. 
All statistical analyses were performed using STATA 15.0 
(StataCorp, College Station, TX, USA). 
RESULTS
Patient Demographics and Biopsy Procedures 
The patient demographics and biopsy procedure 
characteristics grouped by institution are presented in Table 
1. Mean patient age was 65 years (age range, 20–99 years) 
and the proportion of women was 38.0% (3510 of 9239). 
The main guiding modalities were fluoroscopy (used in two 
institutions), conventional CT (three institutions), CBCT (two 
institutions), and CT fluoroscopy (one institution). 
Diagnostic Accuracy
Of the 9384 biopsies, 6774 (72.2%) showed positive 
results, 2170 (23.1%) showed negative results, and 440 
(4.7%) were non-evaluable due to insufficient specimens. 
As for the final diagnosis, 7268 lesions were confirmed 
as malignant and 2116 lesions were confirmed as benign. 
Therefore, the overall accuracy, sensitivity, specificity, PPV, 
and NPV for diagnosis of malignancy were 91.1% (8553 of 
9384; 95% CI, 90.6–91.7%), 92.5% (6723 of 7268; 95% CI, 
91.9–93.1%), 86.5% (1830 of 2116; 95% CI, 85.0–87.9%), 
99.2% (6723 of 6774; 95% CI, 99.0–99.4%), and 84.3% 
(1830 of 2170; 95% CI, 82.7–85.8%), respectively. 
The diagnostic categories and accuracy stratified by 
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lesion size, lesion type, lesion depth, biopsy needle, and 
guiding modality are presented in Tables 2 and 3. Target 
lesions ≤ 2 cm in size had a sensitivity, specificity, PPV, 
and NPV of 88.4% (1508 of 1705; 95% CI, 86.8–89.9%), 
85.0% (599 of 705; 95% CI, 82.1–87.5%), 98.8% (1508 of 
1527; 95% CI, 98.1–99.2%), and 82.8% (599 of 723; 95% 
CI, 79.9–85.5%), respectively. The sensitivity, specificity, 
PPV, and NPV of subsolid pulmonary lesions were 86.1% (304 
of 353; 95% CI, 82.1–89.6%), 85.7% (42 of 49; 95% CI, 
72.8–94.1%), 99.0% (304 of 307; 95% CI, 97.2–99.8%), 
and 60.0% (42 of 70; 95% CI, 47.6–71.5%), respectively. 
In comparison with FNAs, the use of CNBs resulted in a 
lower proportion of non-evaluable results due to insufficient 
specimens (1.3% with CNBs and 8.9% with FNAs). The 
sensitivity, specificity, PPV, and NPV of CNB were 94.9% 
(3833 of 4037; 95% CI, 94.2–95.6%), 96.1% (1108 of 
1153; 95% CI, 94.8–97.1%), 99.7% (3833 of 3846; 95% 
CI, 99.4–99.8%), and 86.7% (1108 of 1278; 95% CI, 
84.7–88.5%), respectively. The sensitivity, specificity, PPV, 
and NPV of FNA were 89.4% (2890 of 3231; 95% CI, 88.3–
90.5%), 75.0% (722 of 963; 95% CI, 72.1–77.7%), 98.7% 
(2890 of 2928; 95% CI, 98.2–99.1%), and 80.9% (722 of 
892; 95% CI, 78.2–83.5%), respectively.
Diagnostic Failures and Risk Factors
The proportions of PTNBs with diagnostic successes and 
diagnostic failures were 91.1% (8553 of 9384; 95% CI, 
90.6–91.7%) and 8.9% (831 of 9384; 95% CI, 8.3–9.4%), 
respectively. The diagnostic success group (n = 8553) 
consisted of 6723 true-positive and 1830 true-negative 
results (Fig. 1). The diagnostic failure group (n = 831) 
consisted of 51 false-positive, 340 false-negative results, 
Table 1. Patient Demographics and Biopsy Procedure Characteristics
Variables Total
Institution
A B C D E F G H
Patient, No. 9239 186 1831 306 1425 429 3133 828 1101
Age (years)
Mean (range) 65 (20–99) 65 (27–91) 65 (21–89) 64 (21–90) 65 (20–91) 71 (20–99) 64 (20–94) 65 (21–93) 65 (20–91)
Women
3510 
(38.0%) 
60 
(32%)
674
(36.8%)
111
(36.3%)
552
(38.7%)
144
(33.6%)
1254
(40.0%)
319
(38.5%)
396
(36.0%)
Smoking history
Never smoker
4082
(44.2%)
115
(61.8%)
690
(37.7%)
145
(47.4%)
642
(45.1%)
163
(38.0%)
1460 
(46.6%)
392
(47.3%)
475
(43.1%)
Former smoker
3293 
(35.6%)
19
(10.2%)
726
(39.7%)
66
(21.6%)
487
(34.2%)
130
(30.3%)
1047 
(33.4%)
305
(36.8%)
513
(46.6%)
Current smoker
1763 
(19.1%)
51
(27.4%)
393
(21.5%)
95
(31.1%)
278
(19.5%)
126
(29.4%)
603
(19.3%)
105
(12.7%)
112
(10.2%)
Familial history of lung cancer
No
8635 
(93.5%)
179 
(96.2%)
1662 
(90.8%)
301
(98.4%)
1351
(94.8%)
408 
(95.1%)
2937 
(93.7%)
798
(96.4%)
999
(90.7%)
Yes 450 (4.9%) 3 (1.6%) 118 (6.4%) 4 (1.3%) 59 (4.1%) 6 (1.4%) 172 (5.5%) 18 (2.2%) 70 (6.4%)
Lesions, No. 9384 188 1853 307 1442 432 3196 854 1112
Lesion size
Median (IQR)
3.0 
(2.0–4.5)
3.8 
(2.4–5.4)
3.2
(2.3–4.7)
3.6 
(2.5–5.6)
3.2 
(2.2–4.7)
3.8 
(2.6–5.5)
2.7 
(1.8–4.0)
3.3 
(2.3–4.9)
2.6 
(1.8–4.0)
Biopsy needle
FNA only
4194 
(44.7%)
1 
(1%)
1698 
(91.6%)
0 
(0%)
1366 
(94.7%)
157
(36.3%)
63 
(2%)
17
(2%)
892
(80.2%)
CNB or combined
5190 
(55.3%)
187 
(99.5%)
155 
(8.4%)
307 
(100.0%)
76
(5%)
275
(63.7%)
3133 
(98.0%)
837 
(98.0%)
220 
(19.8%)
Main guiding 
  modality
CBCT
182 
(96.8%)
Fluoroscopy
1853 
(100.0%)
CT
265 
(86.3%)
CT
1398 
(97.0%)
Fluoroscopy
402 
(93.1%)
CBCT
3193 
(99.9%)
CT
852
(99.8%)
CTF
836 
(75.2%)
Unless otherwise specified, data represent number of biopsies (and percentages). CBCT = cone-beam CT, CNB = core needle biopsy, CTF = 
CT fluoroscopy, FNA = fine needle aspiration, IQR = interquartile range
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and 440 non-evaluable results due to insufficient specimens. 
There was one patient who had false-positive PTNB among 
the 6222 PTNBs that showed malignancy. Although non-
small cell carcinoma was suggested on PTNB, this patient 
was finally diagnosed as having a benign disease (pulmonary 
actinomycosis). 
The diagnostic failure and success groups showed 
differences related to patient age, the presence of 
emphysema, lesion size, lesion type, biopsy needle, 
guiding modality, tissue sample numbers, final diagnosis of 
benignity/malignancy, and final diagnosis of lymphomas (all 
p values < 0.05) (Table 4). Lesion depth and lesion location 
did not significantly increase the risk of diagnostic failure. 
In the multivariable analysis, independent risk factors for 
diagnostic failures were lesion size ≤ 1.0 cm (adjusted odds 
ratio [AOR], 1.86; 95% CI, 1.23–2.81; p = 0.003), lesion size 
of 1.1–2.0 cm (AOR, 1.75; 95% CI, 1.45–2.11; p < 0.001), 
subsolid lesions (AOR, 1.81; 95% CI, 1.32–2.49; p < 0.001), 
FNA only (AOR, 2.43; 95% CI, 1.80–3.28; p < 0.001), final 
diagnosis of benign lesions (AOR, 2.18; 95% CI, 1.84–2.58; 
p < 0.001), and final diagnosis of lymphomas (AOR, 10.66; 
95% CI, 6.21–18.30; p < 0.001). CBCT (AOR, 0.31; 95% CI, 
0.13–0.75; p = 0.009) and conventional CT-guidance (AOR, 
0.55; 95% CI, 0.32–0.94; p = 0.03) reduced diagnostic 
failures when compared with the use of fluoroscopy. 
A final diagnosis of lymphoma was associated with the 
highest proportion of diagnostic failures (36.2%, 25 of 
69). Among the 29 lymphoma cases in which FNAs were 
performed, nearly half (n = 15) showed nonspecific benign 
results, two cases showed non-evaluable results due to 
insufficient specimens, and six cases showed atypical cell 
results. Only six were confirmed as lymphoma with FNA (Fig. 
2). However, diagnoses were made in 75% (30 of 40) of 
lymphoma cases with CNB.
DISCUSSION
In this study, we measured the diagnostic accuracy in 
Table 2. PTNB Diagnostic Categories for Diagnosis of Malignancy Stratified by Lesion Characteristics, Biopsy Needle, and Guiding 
Modality
Factor TP TN FP FN Non-Evaluable*
Lesion size (cm)
≤ 1.0 162 (57.9%) 85 (30.4%) 2 (0.7%) 16 (5.7%) 15 (5.4%)
1.1–2.0 1346 (63.2%) 514 (24.1%) 17 (0.8%) 108 (5.1%) 145 (6.8%)
2.1–3.0 1716 (70.7%) 508 (20.9%) 14 (0.6%) 71 (2.9%) 118 (4.9%)
> 3.0 3498 (77.0%) 722 (15.9%) 18 (0.4%) 145 (3.2%) 162 (3.6%)
Lesion type
Solid 6418 (71.5%) 1788 (19.9%) 48 (0.5%) 312 (3.5%) 415 (4.6%)
Subsolid 304 (75.6%) 42 (10.5%) 3 (0.8%) 28 (7.0%) 25 (6.2%)
Lesion depth (cm)
0 1710 (70.7%) 506 (20.9%) 14 (0.6%) 88 (3.6%) 102 (4.2%)
0.1–1.0 926 (70.1%) 264 (20.0%) 10 (0.8%) 57 (4.3%) 65 (4.9%)
1.1–2.0 1340 (71.9%) 350 (18.8%) 12 (0.6%) 57 (3.1%) 104 (5.6%)
2.1–3.0 1147 (73.4%) 288 (18.4%) 9 (0.6%) 55 (3.5%) 64 (4.1%)
> 3.0 1600 (72.2%) 422 (19.0%) 6 (0.3%) 83 (3.8%) 105 (4.7%)
Biopsy needle
FNA only 2890 (68.9%) 722 (17.2%) 38 (0.9%) 170 (4.1%) 374 (8.9%)
CNB or combined 3833 (73.9%) 1108 (21.4%) 13 (0.3%) 170 (3.3%) 66 (1.3%)
Guiding modality
Fluoroscopy 1906 (75.3%) 305 (12.1%) 24 (1.0%) 90 (3.6%) 206 (8.1%)
CT
Conventional CT 1855 (72.9%) 519 (20.4%) 9 (0.4%) 76 (3.0%) 86 (3.4%)
CTF 512 (61.2%) 143 (17.1%) 6 (0.7%) 74 (8.8%) 102 (12.2%)
CBCT 2379 (70.5%) 848 (25.1%) 11 (0.3%) 96 (2.8%) 42 (1.2%)
Ultrasonography 71 (74.7%) 15 (15.8%) 1 (1.1%) 4 (4.2%) 4 (4.2%)
Total 6723 (71.6%) 1830 (19.5%) 51 (0.5%) 340 (3.6%) 440 (4.7%)
Unless otherwise specified, data represent number of biopsies (and percentages). *Non-evaluable due to insufficient specimens. FN = 
false negative, FP = false positive, PTNB = percutaneous transthoracic needle lung biopsy, TN = true negative, TP = true positive
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Table 3. PTNB Accuracy for Diagnosis of Malignancy Stratified by Lesion Size, Lesion Type, Biopsy Needle, and Guiding Modality
Factor Accuracy Sensitivity Specificity PPV NPV
Lesion size (cm)
≤ 1.0 
88.2 (83.8–91.7) 
[247/280]
87.1 (81.4–91.6) 
[162/186]
90.4 (82.6–95.5) 
[85/94]
98.8 (95.7–99.9) 
[162/164]
84.2 (75.6–90.7)
[85/101]
1.1–2.0
87.3 (85.8–88.7) 
[1860/2130]
88.6 (86.9–90.2) 
[1346/1519]
84.1 (81.0–86.9) 
[514/611]
98.8 (98.0–99.3) 
[1346/1363]
82.6 (79.4–85.5) 
[514/622]
2.1–3.0
91.6 (90.5–92.7) 
[2224/2427]
93.4 (92.2–94.5) 
[1716/1837]
86.1 (83.0–88.8) 
[508/590]
99.2 (98.6–99.6) 
[1716/1730]
87.7 (84.8–90.3) 
[508/579]
> 3.0
92.8 (92.1–93.6) 
[4220/4545]
93.9 (93.1–94.7) 
[3498/3725]
88.0 (85.6–90.2) 
[722/820]
99.5 (99.2–99.7) 
[3498/3516]
83.3 (80.6–85.7) 
[722/867]
Lesion type
Solid
91.4 (91.0–91.9) 
[8206/8981]
92.8 (92.2–93.4) 
[6418/6914]
86.5 (85.0–87.9) 
[1788/2067]
99.3 (99.0–99.5) 
[6418/6466]
85.1 (83.5–86.6) 
[1788/2100]
Subsolid
86.1 (82.3–89.3) 
[346/402]
86.1 (82.1–89.6) 
[304/353]
85.7 (72.8–94.1)
[42/49]
99.0 (97.2–99.8)
[304/307]
60.0 (47.6–71.5) 
[42/70]
Lesion depth (cm)
0
91.6 (90.4–92.6) 
[2216/2420]
93.0 (91.7–94.1) 
[1710/1839]
87.1 (84.1–89.7) 
[506/581]
99.2 (98.6–99.6) 
[1710/1724]
85.2 (82.1–87.9) 
[506/594]
0.1–1.0
90.0 (88.3–91.6) 
[1190/1322]
91.6 (89.7–93.2) 
[926/1011]
84.9 (80.4–88.7) 
[264/311]
98.9 (98.0–99.5)
[926/936]
82.2 (77.6–86.3) 
[264/321]
1.1–2.0
90.7 (89.3–92.0) 
[1690/1863]
93.1 (91.7–94.4) 
[1340/1439]
82.5 (78.6–86.0) 
[350/424]
99.1 (98.5–99.5) 
[1340/1352]
86.0 (82.2–89.2) 
[350/407]
2.1–3.0
91.8 (90.3–93.1)
[1435/1563]
92.8 (91.2–94.2)
[1147/1236]
88.1 (84.1–91.4) 
[288/327]
99.2 (98.5–99.6) 
[1147/1156]
84.0 (79.6–87.7) 
[288/343]
> 3.0
91.2 (90.0–92.4) 
[2022/2216]
91.8 (90.4–93.0) 
[1600/1743]
89.2 (86.1–91.9) 
[422/473]
99.6 (99.2–99.9) 
[1600/1606]
83.6 (80.0–86.7) 
[422/505]
Biopsy needle
FNA only
86.1 (85.0–87.2) 
[3612/4194]
89.4 (88.3–90.5) 
[2890/3231]
75.0 (72.1–77.7) 
[722/963]
98.7 (98.2–99.1) 
[2890/2928]
80.9 (78.2–83.5) 
[722/892]
CNB or combined
95.2 (94.6–95.8) 
[4941/5190]
94.9 (94.2–95.6) 
[3833/4037]
96.1 (94.8–97.1) 
[1108/1153]
99.7 (99.4–99.8) 
[3833/3846]
86.7 (84.7–88.5) 
[1108/1278]
Guiding modality
Fluoroscopy
87.4 (86.0–88.6) 
[2211/2531]
90.5 (89.2–91.7) 
[1906/2106]
71.8 (67.2–76.0) 
[305/425]
98.8 (98.2–99.2) 
[1906/1930]
77.2 (72.8–81.3) 
[305/395]
CT
Conventional CT
93.3 (92.2–94.2) 
[2374/2545]
94.8 (93.7–95.7) 
[1855/1957]
88.3 (85.4–90.8) 
[519/588]
99.5 (99.1–99.8) 
[1855/1864]
87.2 (84.3–89.8) 
[519/595]
CTF
78.3 (75.3–81.0) 
[655/837]
80.1 (76.8–83.2) 
[512/639]
72.2 (65.4–78.3) 
[143/198]
98.8 (97.5–99.6) 
[512/518]
65.9 (59.2–72.2) 
[143/217]
CBCT
95.6 (94.8–96.3) 
[3227/3376]
95.6 (94.7–96.4) 
[2379/2488]
95.5 (93.9–96.8) 
[848/888]
99.5 (99.2–99.8)
[2379/2390]
89.8 (87.7–91.7) 
[848/944]
Ultrasonography
90.5 (82.8–95.6) 
[86/95]
91.0 (82.4–96.3) 
[71/78]
88.2 (63.6–98.5) 
[15/17]
98.6 (92.5–100.0) 
[71/72]
78.9 (54.4–93.9) 
[15/19]
Total
91.1 (90.6–91.7) 
[8553/9384]
92.5 (91.9–93.1) 
[6723/7268]
86.5 (85.0–87.9) 
[1830/2116]
99.2 (99.0–99.4) 
[6723/6774]
84.3 (82.7–85.8) 
[1830/2170]
Unless otherwise specified, data represent percentages, % (95% CI) [numerator/denominator]. CI = confidence interval, NPV = negative 
predictive value, PPV = positive predictive value
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terms of the intention-to-diagnose principle and identified 
the risk factors of diagnostic failures in our dataset, 
which has the largest number of patients yet recorded 
in the literature. Overall, the accuracy, sensitivity, and 
specificity of PTNB for the diagnosis of malignancy were 
91.1%, 92.5%, and 86.5%, respectively. Diagnostic failures 
occurred in 8.9% of the PTNB cases. The risk factors for 
diagnostic failures were target lesion size ≤ 2 cm, subsolid 
lesions, FNA only, a final diagnosis of benign lesions, and 
final diagnosis of lymphomas. Conventional CT and CBCT 
significantly lowered the proportion of diagnostic failures, 
when compared with fluoroscopy. 
The specificity of PTNBs was 86.5%, which is much lower 
than the previously reported values of 98–100% (3-8). 
We think that the specificity in the previous studies was 
overestimated because the specificities in these studies 
were calculated by excluding the non-evaluable results (4, 
5, 8) or regarding non-evaluable categories as negative 
results (7, 14). In this study, however, the specificity was 
calculated according to the intention-to-diagnose principle 
by including non-evaluable results due to insufficient 
specimens as false positives (9).
In a previous multicenter study (7), the NPV was only 
51% when nonspecific benign pathologic results and 
non-evaluable results due to insufficient specimens were 
regarded as negative results. Because the clinical meanings 
of nonspecific benign pathologic results and non-evaluable 
results due to insufficient specimens might be substantially 
different in actual clinical practice, we did not consider 
non-evaluable results due to insufficient specimens as 
negative results. Indeed, the proportion of final diagnosis 
of malignancy was much higher among the non-evaluable 
results due to insufficient specimens (46.6%) than that 
among the nonspecific benign results (21.3%). When we 
measured the NPV in the nonspecific benign category, the 
NPV was 78.7%. 
Target lesion size ≤ 2 cm and the presence of subsolid 
pulmonary lesions were risk factors for diagnostic failures. 
These findings are consistent with studies that reported 
smaller lesions were associated with higher diagnostic 
failures (3, 6, 8), although the diagnostic accuracy of PTNBs 
in target lesions ≤ 2 cm in size remained at a relatively 
high level. Target lesions over 3 or 5 cm in size were not 
associated with high diagnostic failures in our study, in 
contrast to the previous studies (3, 15). Careful selection of 
the target area might have prevented diagnostic failures for 
large lesions with necrosis. With subsolid lesions, the NPV 
was only 60.0%, and the proportion of diagnostic failures 
Fig. 1. Axial CT images in 78-year-old man with history of esophageal cancer.
A. Contrast-enhanced chest CT image shows 1.3-cm solid nodule in right upper lobe (arrow). B. CT-guided PTNB was performed by using 22-gauge 
aspiration needle, and pathologic examination showed adenocarcinoma of pulmonary origin (true-positive result). Patient underwent right upper 
lobectomy, and lesion was confirmed to be adenocarcinoma in pathologic examination. PTNB = percutaneous transthoracic needle lung biopsy
A B
1307
Diagnostic Accuracy of PTNBs: A Multicenter Study
https://doi.org/10.3348/kjr.2019.0189kjronline.org
increased to 13.9%. Because part-solid nodules have a 
high probability of malignancy (16), our results support 
direct surgical resections in part-solid nodules based on CT 
assessments (17). 
Although there was no control over the biopsy needle 
selection, the strength of our study was that the accuracies 
of FNA and CNB were compared in a multi-institutional 
setting. Since only small tissue samples can be obtained 
with FNA, each institution’s FNA accuracy may vary 
depending on the target lesions’ characteristics, aspiration 
techniques, the presence of on-site pathologists, and the 
experience levels of the interpreting pathologists (18). 
In this study, CNB showed a much lower proportion of 
non-evaluable results due to insufficient specimens than 
did FNA, and FNA was found to be an independent risk 
factor for diagnostic failures. The specificity of PTNBs 
Table 4. Diagnostic Failures and Their Risk Factors
Variable
Diagnostic Failure
Percentage, % (95% CI)
[Numerator/Denominator]
P*
Multivariable Analysis, 
AOR (95% CI)
P†
Age (years) < 0.001
≤ 65 9.9% (9.0–10.8%) [440/4451] 1 (Reference)
> 65 7.9% (7.2–8.7%) [391/4933] 0.89 (0.76–1.04) 0.13
Sex 0.07 - -
Male 8.6% (7.8–9.3%) [498/5822]
Female 9.4% (8.4–10.4%) [333/3562]
Emphysema 0.04
No 8.7% (8.0–9.3%) [600/6936] 1 (Reference)
Yes 9.4% (8.3–10.7%) [231/2447] 1.02 (0.86–1.22) 0.79
Lesion size (cm) < 0.001
≤ 1.0 11.8% (8.3–16.2%) [33/280] 1.86 (1.23–2.81) 0.003
1.1–2.0 12.7% (11.3–14.2%) [270/2130] 1.75 (1.45–2.11) < 0.001
2.1–3.0 8.4% (7.3–9.5%) [203/2427] 1.03 (0.85–1.25) 0.77
> 3.0 7.2% (6.4–7.9%) [325/4545] 1 (Reference)
Lesion type 0.002
Solid 8.6% (8.1–9.2%) [775/8981] 1 (Reference)
Subsolid 13.9% (10.7–17.7%) [56/402] 1.81 (1.32–2.49) < 0.001
Biopsy needle < 0.001
FNA only 13.9% (12.8–15.0%) [582/4194] 2.43 (1.80–3.28) < 0.001
CNB or combined 4.8% (4.2–5.4%) [249/5190] 1 (Reference)
Guiding modality
Fluoroscopy 12.6% (11.4–14.0%) [320/2531] 1 (Reference)
CT < 0.001
Conventional CT 6.7% (5.8–7.8%) [171/2545] 0.55 (0.32–0.94) 0.03
CTF 21.7% (19.0–24.7%) [182/837] 0.88 (0.59–1.31) 0.52
CBCT 4.4% (3.7–5.2%) [149/3376] 0.31 (0.13–0.75) 0.009
Ultrasonography 9.5% (4.4–17.2%) [9/95] 0.88 (0.36–2.13) 0.78
No. of tissue samplings 0.01
≤ 2 11.5% (10.7–12.3%) [675/5874] 1.07 (0.79–1.45) 0.65
≥ 3 4.4% (3.7–5.1%) [140/3203] 1 (Reference)
Final diagnosis < 0.001
Benign 13.5% (12.1–15.0%) [286/2116] 2.18 (1.84–2.58) < 0.001
Malignant 7.5% (6.9–8.1%) [545/7268] 1 (Reference)
Lymphoma < 0.001
No 8.7% (8.1–9.2%) [806/9315] 1 (Reference)
Yes 36.2% (25.0–48.7%) [25/69] 10.66 (6.21–18.30) < 0.001
*p values from univariable analyses, †p values from multivariable analysis. AOR = adjusted odds ratio
1308
Lee et al.
https://doi.org/10.3348/kjr.2019.0189 kjronline.org
was significantly higher with CNB (96.1%) than with FNA 
(75.0%). CNB can be a better option than FNA to reduce 
the risk of diagnostic failure of PTNB, especially for lung 
lesions with a high risk of diagnostic failure. Although 
we did not include the results of the molecular analysis 
in this study, CNB has been preferred over FNA to obtain 
adequate tissue for molecular analysis (19, 20). However, it 
should be noted that CNB has been associated with higher 
complication rates (21). Radiologists should choose the 
type of biopsy needles carefully in a given case, considering 
the possible impact of diagnostic failure and occurrence of 
complications.
The guiding modality is usually determined on the 
basis of accessibility, target lesion characteristics, and 
operator preferences. Each modality has its advantages and 
disadvantages; it is difficult to identify a single modality 
of choice for PTNBs. In this study, biopsies performed 
under CBCT were associated with the lowest percentage 
of diagnostic failures. However, there was no significant 
difference between CBCT and conventional CT. Because of 
the flexibility of CBCT with regard to orienting detectors 
around patients, this technique has shown high diagnostic 
accuracy even with small lesions (5). Nonetheless, 
radiologists are exposed to fluoroscopic radiation during 
CBCT-guided biopsy. Conventional CT is accessible in most 
institutions and does not expose radiologists to radiation. 
However, conventional CT may be related to more patient 
radiation exposure than CBCT (22). The guidance under CT 
fluoroscopy did not show higher diagnostic performance 
when compared to fluoroscopy. We speculate that the high 
proportion of diagnostic failures under CT fluoroscopy may 
be institution-specific and related to lesion characteristics 
and aspiration techniques, but not an issue with CT 
fluoroscopy (11).
This study had the following limitations. First, it was 
retrospective, and the biopsy practice pattern differed 
across institutions depending on preferences, resources, 
and operators’ experience. There was no control over the 
biopsy decision processes. Second, pre-test probabilities 
of malignancy and detailed biopsy indications were not 
evaluated in this retrospective study. However, the majority 
of the PTNBs were performed for the diagnosis of lung 
lesions considered to be malignant. Third, diagnostic 
failures or accuracies could not be evaluated in patients 
with incomplete reference standards for final diagnosis, 
although the proportion of such patients was small (5.9%). 
Fig. 2. Axial CT images in 21-year-old man diagnosed with acquired immunodeficiency syndrome. He was referred for incidentally 
detected pulmonary mass during treatment of Pneumocystis jiroveci pneumonia.
A. Contrast-enhanced chest CT image shows 4.0-cm mildly enhanced mass in left lower lobe (arrow). B. CT-guided PTNB was performed by using 
22-gauge aspiration needle, and pathologic examination showed chronic inflammation (false-negative result). Patient underwent left lower 
lobectomy, and lesion was confirmed to be malignant lymphoma in pathologic examination.
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Fourth, technical failure cases, operator-related factors, and 
procedure times were not evaluated. Fifth, no institution 
had on-site pathologists. 
In conclusion, the accuracy of PTNB for diagnosis 
of malignancy was fairly high in our large-scale multi-
institutional cohort. The identified risk factors for 
diagnostic failure may help reduce diagnostic failure and 
interpret the biopsy results.
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